Multi-Million-Dollar Deal Brings UQ Pain Drug Closer to Reality

J William M Tweedie

Well-Known Member
Tue, 06/30/2015 - 8:18am
University of Queensland
A chronic pain treatment discovered at The University of Queensland is a step closer to clinical use, with a global pharmaceutical giant acquiring the Australian-founded company developing the drug.

Spinifex Pharmaceuticals has been acquired by Novartis International AG for an upfront cash payment of $US200 million (about $A260 million), plus undisclosed clinical development and regulatory milestone payments.

Spinifex is a biopharmaceutical company founded by UQ commercialisation arm UniQuest.

UQ Vice-Chancellor and President Professor Peter Høj welcomed the acquisition and congratulated those involved.
“This is one of the largest Australian biotech deals in history, and is a stunning outcome for the company, the researchers and the investors,” Professor Høj said.

“Spinifex builds on the unprecedented commercial translation achievements of UQ, which includes the world’s first cancer vaccine, Gardasil.
“It is a shining example of UQ’s determination to take research from excellence to what I call ‘excellence plus’, developing a product that has potential to improve the lives of people around the world.”

Spinifex is developing the drug candidate EMA401, an oral treatment for chronic pain, particularly neuropathic pain (a type of nerve pain), without central nervous system side effects.

The technology is based on a discovery by UQ’s Professor Maree Smith.

Professor Smith said the acquisition brought EMA401 a step closer to the people who needed it most.

“Chronic pain can be a debilitating condition, most commonly associated with cancer chemotherapy, post-herpetic neuralgia (a painful condition that can follow shingles), diabetes, peripheral nerve injury and osteoarthritis.

“It’s wonderful to see this deal eventuate, bringing a much-needed treatment option a little closer to reality for the millions of pain sufferers around the world,” Professor Smith said.

UniQuest CEO Dr Dean Moss said Dr Smith’s work was at the cutting edge of pain research.

“Her achievements and expertise have contributed to the formation of the recently-launched Queensland Emory Drug Discovery Initiative (QEDDI),” Dr Moss said.

QEDDI, a collaboration between UQ and Emory University in the US, will see the development of drugs to combat health issues including cancer, diabetes, inflammatory disorders and infectious diseases.

EMA401 is a novel angiotensin II type 2 (AT2) receptor antagonist being developed as a potential first-in-class oral treatment.

Professor Smith and UQ's Dr Bruce Wyse’s research identified AT2 receptor antagonists as inhibitors of neuropathic and inflammatory pain in preclinical models.

Source: University of Queensland
 

JennyJenny

Well-Known Member
Great news. My problem is my insurance will put it on a Tier 4 and then Tier 3 maybe 5 years later if they cover it at all.

But glad it will be available to others.
 

J William M Tweedie

Well-Known Member
That's why we need wider awareness and stronger advocacy, Jenny. Something like this might get to market faster and be covered by insurance with a global giant, Novartis, at the helm. Fingers crossed...
 

Shannon

Member
I'm always grateful of the information found on this site. This is awesome news, even if it's probably a few years before we'd see the drug in North America.

Thanks for sharing! :rolleyes:
 

Cort

Founder of Health Rising and Phoenix Rising
Staff member
Astounding stuff! I had no idea....$200 million is big bucks. They must be confident this drug will succeed....

Very hopeful - thanks!
 

Cort

Founder of Health Rising and Phoenix Rising
Staff member
Yes indeed! Keep them coming...I found a good amount of research on this drug....- probably do a blog on it. Love to get hopeful news out :)
 

Forum Tips

Support Our Work

DO IT MONTHLY

HEALTH RISING IS NOT A 501 (c) 3 NON-PROFIT

Shopping on Amazon.com For HR

Latest Resources

Top